ACC's October Board of Trustees (BOT) meeting was rich with strategic dialogue and forward-looking initiatives that reflect our shared commitment to advancing cardiovascular care and strengthening the ...
A new nasal spray form of bumetanide may reduce the tissue swelling caused by heart failure (HF) as effectively as the standard oral and intravenous formulations of the loop diuretic, based on ...
A single infusion of a CRISPR-based gene editing therapy significantly reduced LDL-C and PCSK9 levels in patients with heterozygous familial hypercholesterolemia (HeFH), based on findings from the ...
Popular anti-obesity drugs continue to show cardiovascular benefits beyond weight loss, according to new research published in JACC and simultaneously presented at AHA 2024. Among the highlights: ...
The proposed 2026 Medicare Physician Fee Schedule (PFS) includes a proposal to reduce the physician work relative value unit (RVU) for performing a left atrial appendage closure procedure (LAAO) from ...
The U.S. Food and Drug Administration (FDA) has approved the FARAPULSE Pulsed Field Ablation System for isolation of pulmonary veins in the treatment of drug-refractory, recurrent, symptomatic, ...
Late-breaking results from the PROMPT-AF, CRRF-PeAF, TRIM-AF and ARREST-AF trials presented at AHA 2024 shed new light on cutting-edge approaches to revolutionizing the management of patients with ...
The federal government shut down on Oct. 1 as lawmakers failed to reach a funding agreement. According to contingency plans from the Centers for Medicare and Medicaid Services (CMS), operations such ...
The Centers for Medicare and Medicaid Services (CMS) has released the 2026 Medicare Physician Fee Schedule (PFS) proposed rule, updating the PFS conversion factor from $32.3465 to $33.5875 for ...
The Centers for Medicare and Medicaid Services (CMS) has proposed a change in methodology to indirect practice expense (PE) payment in the proposed 2026 Medicare Physician Fee Schedule (PFS), which ...
The number of cardiac procedures being performed in ambulatory surgery centers (ASCs) has grown significantly over the last decade, and third-party payer reimbursement, led by the Centers for Medicare ...
The U.S. Food and Drug Administration (FDA) has approved the Sapien 3, Sapien 3 Ultra and Sapien 3 Ultra Resilia TAVR valves from Edwards Lifesciences to treat patients with asymptomatic severe aortic ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback